BOSTON, Aug. 15, 2024 /PRNewswire/ -- Haemonetics Corporation (NYSE: HAE), a global medical technology company focused on delivering innovative solutions to drive better patient outcomes, today announced the full market release of its VASCADE MVP® XL mid-bore venous closure system. The VASCADE MVP XL system is now available to U.S. hospitals as the newest addition to Haemonetics' VASCADE® portfolio of vascular closure systems featuring an innovative collapsible disc technology and a proprietary resorbable c ...

Haemonetics Corporation (HAE) delivered adjusted earnings per share (EPS) of $1.02 in the first quarter of fiscal 2025, down 2.9% year over year. The bottom line missed the Zacks Consensus Estimate by 0.9%. On a GAAP basis, the EPS was 74 cents compared with 80 cents in the prior-year quarter. Total Revenues Revenues increased 8% (up 2.8% on an organic basis) to $336.2 million in the first quarter of fiscal 2025. The top line beat the Zacks Consensus Estimate by 0.1%. Segments in Detail At Plasma, revenues ...

While the proven Zacks Rank places an emphasis on earnings estimates and estimate revisions to find strong stocks, we also know that investors tend to develop their own individual strategies. With this in mind, we are always looking at value, growth, and momentum trends to discover great companies. Looking at the history of these trends, perhaps none is more beloved than value investing. This strategy simply looks to identify companies that are being undervalued by the broader market. Value investors use a ...

Core Viewpoint - Haemonetics (HAE) has experienced significant selling pressure, resulting in a 14.6% decline in stock price over the past four weeks, but analysts anticipate better earnings than previously predicted, indicating potential for recovery [1]. Group 1: Stock Performance and Indicators - HAE shares are currently in oversold territory, with a Relative Strength Index (RSI) reading of 28.12, suggesting a possible reversal in trend [3]. - The stock's heavy selling appears to be exhausting, indicating a potential return to equilibrium in supply and demand [3]. Group 2: Earnings Estimates and Analyst Sentiment - There has been a consensus among sell-side analysts to raise earnings estimates for HAE, resulting in a 0.2% increase in the consensus EPS estimate over the last 30 days [3]. - An upward trend in earnings estimate revisions typically correlates with price appreciation in the near term [3]. - HAE holds a Zacks Rank 2 (Buy), placing it in the top 20% of over 4,000 ranked stocks based on earnings estimate revisions and EPS surprises, further supporting the stock's potential for a turnaround [3].

Core Viewpoint - Haemonetics reported quarterly earnings of $1.02 per share, slightly missing the Zacks Consensus Estimate of $1.03 per share, and down from $1.05 per share a year ago [1][2] Financial Performance - The company posted revenues of $336.17 million for the quarter ended June 2024, surpassing the Zacks Consensus Estimate by 0.09% and up from $311.33 million year-over-year [3] - Over the last four quarters, Haemonetics has exceeded consensus revenue estimates three times [3] Stock Performance and Outlook - Haemonetics shares have increased by approximately 0.3% since the beginning of the year, while the S&P 500 has gained 9% [4] - The current consensus EPS estimate for the upcoming quarter is $1.11 on revenues of $346.75 million, and for the current fiscal year, it is $4.58 on revenues of $1.39 billion [8] Industry Context - The Medical - Products industry, to which Haemonetics belongs, is currently ranked in the top 34% of over 250 Zacks industries, indicating a favorable outlook [9] - Empirical research suggests a strong correlation between near-term stock movements and trends in earnings estimate revisions, which can impact Haemonetics' stock performance [6][7]

Shares of Haemonetics (HAE) have gained 2.4% over the past four weeks to close the last trading session at $86.20, but there could still be a solid upside left in the stock if short-term price targets of Wall Street analysts are any indication. Going by the price targets, the mean estimate of $112.17 indicates a potential upside of 30.1%. The average comprises six short-term price targets ranging from a low of $94 to a high of $125, with a standard deviation of $10.87. While the lowest estimate indicates an ...

CLEVELAND, Aug. 01, 2024 (GLOBE NEWSWIRE) -- Sotera Health Company (Nasdaq: SHC), a leading global provider of mission-critical end-to-end sterilization solutions and lab testing and advisory services for the healthcare industry, announced today it has appointed Christopher Simon as a new independent director to its Board of Directors. Mr. Simon will serve as a member of the Leadership Development and Compensation Committee of the Board of Directors. For approximately the past eight years, Mr. Simon has ser ...

BOSTON, July 30, 2024 /PRNewswire/ -- Haemonetics Corporation (NYSE: HAE), a global medical technology company focused on delivering innovative medical solutions to drive better patient outcomes, today announced CE Mark certification and the first commercial European procedures for the SavvyWire® PreShaped Pressure Guidewire. The SavvyWire guidewire is the world's first and only sensor-guided 3-in-1 solution for Transcatheter Aortic Valve Implantation (TAVI), designed to improve procedural efficiency with p ...

Core Insights - Haemonetics Corporation has received CE Mark certification for its SavvyWire guidewire, which is the first sensor-guided 3-in-1 solution for Transcatheter Aortic Valve Implantation (TAVI) [8] - The SavvyWire guidewire is designed to enhance procedural efficiency by providing predictable wire performance, hemodynamic measurement, and left-ventricular pacing capabilities [8][10] - The first commercial procedures using the SavvyWire guidewire were successfully performed in Europe, specifically at CHU Bordeaux in France and Catharina Ziekenhuis Eindhoven in the Netherlands [4][8] Company Overview - Haemonetics is a global medical technology company focused on delivering innovative medical solutions aimed at improving patient outcomes [8][11] - The company has expanded its product portfolio with the acquisition of OpSens Inc. in December 2023, which included the SavvyWire guidewire [4] - Haemonetics aims to leverage its global commercial infrastructure to enhance access to critical interventional technologies across Europe, the Middle East, and Africa [5] Product Features - The SavvyWire guidewire allows for multiple procedural steps over the same guidewire, reducing the need for device exchanges and enabling continuous monitoring of cardiac hemodynamics [10] - It is engineered to support reliable left-ventricular pacing without the need for additional devices or venous access, streamlining the TAVI procedure [10] - The guidewire's capabilities are expected to raise the standard for hemodynamic measurements during TAVI, allowing for immediate procedural decision-making by physicians [11]

Haemonetics (HAE) is scheduled to report first-quarter fiscal 2025 results on Aug 8, before market open. In the last reported quarter, the company's adjusted earnings per share (EPS) of 90 cents surpassed the Zacks Consensus Estimate by 2.27%. The Zacks Consensus Estimate for EPS of $1.03 indicates a year-over-year decline of 1.9%. Let's take a look at how things might have shaped up for the MedTech major prior to the announcement. Hospital revenues in the fiscal first quarter are once again expected to hav ...